Cancer Genetics: Enabling Precision Medicine for Oncology

Oct. 12, 2017
Cancer Genetics, Inc. (NASDAQ:) is an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information. CGIX’s tests, which target difficult to diagnose hematological, urogenital and HPV-associated cancers, are designed to guide prognosis and treatment with the goal of improving outcomes for patients. CGIX is developing a global footprint with locations in the US, India and China. It has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC, and the National Cancer Institute, and its state-of-the-art reference labs are CLIA-certified and CAP-accredited with licensure from several states including New York State.

 Read More

Search Our Video Library

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market